Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.3661
-0.0611 (-14.30%)
At close: Nov 24, 2025, 4:00 PM EST
0.3550
-0.0111 (-3.03%)
Pre-market: Nov 25, 2025, 6:04 AM EST
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$3,024,176
Market Cap
18.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | -1 | -5.26% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | 17 | 2 | 13.33% |
| Dec 31, 2020 | 15 | -1 | -6.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MBRX News
- 11 days ago - Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented - GlobeNewsWire
- 12 days ago - Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill - GlobeNewsWire
- 25 days ago - Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting - GlobeNewsWire
- 26 days ago - Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin - GlobeNewsWire
- 4 weeks ago - Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin - GlobeNewsWire
- 2 months ago - Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial - GlobeNewsWire
- 2 months ago - Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - GlobeNewsWire